Coalition Letter Opposes Price Regulation of Lower Priced Generic Drugs

Dear Members of the Committee on Health Coverage, Insurance and Financial Services: As state and national organizations representing a wide range of U.S. taxpayers and consumers, we write today in opposition to LD 1117, Maine’s Act To Prevent Excessive Prices for Prescription Drugs, which seeks to impose pricing constraints on generic drug manufacturers. While working […]

The Hill: Competition, Not Capping Increases, is the Cure for High Drug Prices

Soaring prescription drug prices are putting financial pressure on families across the country. In response, state legislators are increasingly considering limits on the annual price increase of prescription drugs. But rather than making drugs more affordable, these policies risk reducing consumer access to cheaper, generic alternatives. Read this op-ed in The Hill       […]

Coalition Calls for Increased Generic Drug Competition

While the Lower Health Care Costs Act is intended to increase competition and patient access to lower cost medicines, section 205 of the bill needs to address FDA concerns about the “parking” of generic applications. We believe generic manufacturers need to launch new medications into the market as soon as possible after approval. However, as […]

ACI Coaltion Letter Sent To FDA

A coalition of nonprofit think tanks sent a letter to FDA Commissioner Sharpless urging reforms to current regulatory regulations that are impeding market competition between drug makers. The letter states that increasing market competition is the best means for price reductions, which will lower medical program costs, taxpayer burdens, and out-of-pocket expenses for consumers, as […]